In the hunt for a $100M IPO, Biohaven polishes up discards from Bristol-Myers, AstraZeneca
When Biohaven Pharmaceutical spun out of Yale a few years ago, company executives talked a lot about their focus on depression and anxiety …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
